$ Value
$900K
Shares
6,560
Price
$137
Filed
Jan 30
Insider
Name
Sampath Anand
Title
EVP, Ops & Clinical Research
CIK
0001406493
Roles
Transaction Details
Transaction Date
2026-01-28
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
41,105
Footnotes
The shares covered by this Form 4 were exercised and sold pursuant to a Rule 10b5-1 Sales Plan dated as of September 12, 2025, which is intended to comply with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. | The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $135.94 per share to a high of $136.94 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. | The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $136.95 per share to a high of $137.89 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. | The price reported in Column 4 represents the weighted average purchase price per share. The actual sale prices ranged from a low of $138.07 per share to a high of $138.12 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. | This option was granted on February 29, 2016 and is exercisable as the option vests. The option vested over a 5 year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date.
Filing Info
Sampath Anand's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-06 | MASI | A | $0 |
| 2026-01-28 | MASI | M | $1.1M |
| 2026-01-28 | MASI | ▼ | $1.6M |
| 2026-01-28 | MASI | ▼ | $900K |
| 2026-01-28 | MASI | ▼ | $27K |
| 2026-01-28 | MASI | M | $0 |
Other Insiders at MASI (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Sampath Anand
EVP, Operations
|
— | — | 2026-03-06 |
|
Sampath Anand
EVP, Ops & Clinical Research
|
— | $1.7M | 2026-01-28 |
|
Szyman Catherine M.
CEO
|
— | — | 2026-03-06 |
|
Dadswell Charles
EVP, General Counsel
|
— | — | 2026-03-06 |
|
Young Micah W
EVP & Chief Financial Officer
|
— | — | 2026-03-06 |
|
Benner Tim
Chief Marketing Officer
|
— | — | 2026-03-06 |
|
Hellmann Elisabeth A
Chief Human Resources Officer
|
— | — | 2026-03-06 |
|
Meehan Greg Allen
Chief Commerical Officer
|
— | — | 2026-03-06 |